Literature DB >> 18327668

Polymorphism in environment responsive genes and association with Parkinson disease.

Madhu Singh1, Anwar J Khan, Parag P Shah, Rakesh Shukla, V K Khanna, Devendra Parmar.   

Abstract

Attempts were made in the present case-control study to investigate the association of polymorphism in the genes encoding proteins involved in toxication-detoxication and dopaminergic pathways and susceptibility to Parkinson's disease (PD). Seventy patients suffering from PD and one hundred healthy controls belonging to the same geographical location and same ethnicity were included in the study. PCR-RFLP and allele-specific PCR-based methodology were used to identify the genotypes. Multivariate logistic regression analysis revealed that heterozygous genotypes of cytochrome P4502D6*4(CYP2D6*4), CYP2E1*5B (RsaI) polymorphism and homozygous mutant genotypes of CYP2E1*6 (Dra1) were found to be overrepresented in PD cases when compared to the controls. Risk was also found to be increased in patients carrying glutathione S-transferase T1 (GSTT1) null or homozygous variant genotypes of GSTP1. Significant association was observed for monoamine oxidase-B(MAO-B) variant allele G and PD, whereas no difference in genotype and allele frequencies was observed for manganese-superoxide dismutase (MnSOD), dopamine receptor-D2(DRD2), and dopamine transporter (DAT) genes between controls and PD cases. Genotype combinations characterized by the presence of two variant genotypes on their corresponding loci revealed that four combinations of GSTT1 null and MnSOD(-9Val) or GST null and MAOB-G or CYP2E1*5B and MAO-B-AG or CYP2E1*5B and DRD2 (Taq1A-het) genotypes in the patients exhibited severalfold higher and significant association with risk to PD. Our data suggest that polymorphism in the genes involved in detoxification and dopamine regulation may modulate the susceptibility to PD and could be important risk factors in the pathogenesis of PD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18327668     DOI: 10.1007/s11010-008-9728-2

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  34 in total

1.  Dopamine D2 receptor TaqIA and TaqIB polymorphisms in Parkinson's disease.

Authors:  Eng-King Tan; Yanni Tan; Anthea Chai; Christopher Tan; Hui Shen; Sau-Ying Lum; Stephanie M C Fook-Cheong; Mei-Ling Teoh; Yuan Yih; Meng-Cheong Wong; Yi Zhao
Journal:  Mov Disord       Date:  2003-05       Impact factor: 10.338

2.  Case-control study of the D2 dopamine receptor gene and smoking status in lung cancer patients.

Authors:  M R Spitz; H Shi; F Yang; K S Hudmon; H Jiang; R M Chamberlain; C I Amos; Y Wan; P Cinciripini; W K Hong; X Wu
Journal:  J Natl Cancer Inst       Date:  1998-03-04       Impact factor: 13.506

Review 3.  Genotyping of cytochrome P450 2D6*3 and *4 mutations using conventional PCR.

Authors:  B C Schur; J Bjerke; N Nuwayhid; S H Wong
Journal:  Clin Chim Acta       Date:  2001-06       Impact factor: 3.786

4.  Association study for Parkinson's disease and a dopamine transporter gene polymorphism (1215A/G).

Authors:  Chien-Nan Lin; Hsiu-Chih Liu; Shih-Jen Tsai; Tsung-Yun Liu; Chen-Jee Hong
Journal:  Eur Neurol       Date:  2002       Impact factor: 1.710

5.  Genetic polymorphisms of superoxide dismutase in Parkinson's disease.

Authors:  F M Farin; Y Hitosis; S E Hallagan; J Kushleika; J S Woods; P S Janssen; T Smith-Weller; G M Franklin; P D Swanson; H Checkoway
Journal:  Mov Disord       Date:  2001-07       Impact factor: 10.338

6.  Analysis of mitochondrial targeting sequence and coding region polymorphisms of the manganese superoxide dismutase gene in German Parkinson disease patients.

Authors:  E M Grasbon-Frodl; S Kösel; O Riess; U Müller; P Mehraein; M B Graeber
Journal:  Biochem Biophys Res Commun       Date:  1999-02-24       Impact factor: 3.575

Review 7.  Pharmacogenomics of neurodegenerative diseases.

Authors:  D Maimone; R Dominici; L M Grimaldi
Journal:  Eur J Pharmacol       Date:  2001-02-09       Impact factor: 4.432

8.  Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism.

Authors:  S Pemble; K R Schroeder; S R Spencer; D J Meyer; E Hallier; H M Bolt; B Ketterer; J B Taylor
Journal:  Biochem J       Date:  1994-05-15       Impact factor: 3.857

Review 9.  Alpha-synuclein and Parkinson's disease.

Authors:  Alessandra Recchia; Patrizia Debetto; Alessandro Negro; Diego Guidolin; Stephen D Skaper; Pietro Giusti
Journal:  FASEB J       Date:  2004-04       Impact factor: 5.191

10.  CYP2D6 gene polymorphism as a probable risk factor for Alzheimer's disease and Parkinson's disease with dementia.

Authors:  Monika Gołab-Janowska; Krystyna Honczarenko; Barbara Gawrońska-Szklarz; Andrzej Potemkowski
Journal:  Neurol Neurochir Pol       Date:  2007 Mar-Apr       Impact factor: 1.621

View more
  32 in total

1.  Cytochrome P450-2D6 extensive metabolizers are more vulnerable to methamphetamine-associated neurocognitive impairment: preliminary findings.

Authors:  Mariana Cherner; Chad Bousman; Ian Everall; Daniel Barron; Scott Letendre; Florin Vaida; J Hampton Atkinson; Robert Heaton; Igor Grant
Journal:  J Int Neuropsychol Soc       Date:  2010-08-23       Impact factor: 2.892

2.  Multifactor dimensionality reduction analysis to elucidate the cross-talk between one-carbon and xenobiotic metabolic pathways in multi-disease models.

Authors:  Shaik Mohammad Naushad; Sana Venkata Vijayalakshmi; Yedluri Rupasree; Nadella Kumudini; Sampathkumar Sowganthika; Janardhanan Venketlakshmi Naidu; M Janaki Ramaiah; Dunna Nageswara Rao; Vijay Kumar Kutala
Journal:  Mol Biol Rep       Date:  2015-02-04       Impact factor: 2.316

3.  APOE and CYP2E1 polymorphisms, alcohol consumption, and Parkinson's disease in a Japanese population.

Authors:  Chikako Kiyohara; Yoshihiro Miyake; Midori Koyanagi; Takahiro Fujimoto; Senji Shirasawa; Keiko Tanaka; Wakaba Fukushima; Satoshi Sasaki; Yoshio Tsuboi; Tatsuo Yamada; Tomoko Oeda; Takami Miki; Nobutoshi Kawamura; Nobutaka Sakae; Hidenao Fukuyama; Yoshio Hirota; Masaki Nagai
Journal:  J Neural Transm (Vienna)       Date:  2011-03-01       Impact factor: 3.575

4.  Manganese exposure exacerbates progressive motor deficits and neurodegeneration in the MitoPark mouse model of Parkinson's disease: Relevance to gene and environment interactions in metal neurotoxicity.

Authors:  Monica R Langley; Shivani Ghaisas; Muhammet Ay; Jie Luo; Bharathi N Palanisamy; Huajun Jin; Vellareddy Anantharam; Arthi Kanthasamy; Anumantha G Kanthasamy
Journal:  Neurotoxicology       Date:  2017-06-20       Impact factor: 4.294

5.  A genome-wide linkage screen in the Amish with Parkinson disease points to chromosome 6.

Authors:  Anna C Cummings; Stephen L Lee; Jacob L McCauley; Lan Jiang; Amy Crunk; Lynne L McFarland; Paul J Gallins; Denise Fuzzell; Clare Knebusch; Charles E Jackson; William K Scott; Margaret A Pericak-Vance; Jonathan L Haines
Journal:  Ann Hum Genet       Date:  2011-05       Impact factor: 1.670

6.  Comparative analysis of four disease prediction models of Parkinson's disease.

Authors:  Nadella Kumudini; Shaik Mohammad Naushad; Balraj Alex Stanley; Manoharan Niveditha; Gunasekaran Sharmila; Konda Kumaraswami; Rupam Borghain; Rukmini Mridula; Vijay Kumar Kutala
Journal:  Mol Cell Biochem       Date:  2015-10-05       Impact factor: 3.396

7.  SLC6A3 is a risk factor for Parkinson's disease: a meta-analysis of sixteen years' studies.

Authors:  Desheng Zhai; Songji Li; Ying Zhao; Zhicheng Lin
Journal:  Neurosci Lett       Date:  2013-11-07       Impact factor: 3.046

8.  Genomic features of the human dopamine transporter gene and its potential epigenetic States: implications for phenotypic diversity.

Authors:  Elena Shumay; Joanna S Fowler; Nora D Volkow
Journal:  PLoS One       Date:  2010-06-10       Impact factor: 3.240

9.  Brain insulin-like growth factor and neurotrophin resistance in Parkinson's disease and dementia with Lewy bodies: potential role of manganese neurotoxicity.

Authors:  Ming Tong; Matthew Dong; Suzanne M de la Monte
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

10.  Null genotype of GSTT1 contributes to increased Parkinson's disease risk in Caucasians: evidence from a meta-analysis.

Authors:  Dan Wang; Jun-Xia Zhai; Li-Mei Zhang; Dian-Wu Liu
Journal:  Mol Biol Rep       Date:  2014-08-03       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.